These findings, together with clinical observations of elevated TIMP-1 levels in multiple cancers including breast cancer, established an “oncogenic” function of TIMP-1, seemingly paradoxical to the “tumor suppressive” activity of TIMP-1 thought to be mediated by its well-established ability to inhibit metalloproteinase activity (reviewed in [14,20]). Here, TIMP1 is linked to cancer.